Terms: = Breast cancer AND VHL, HRCA1, P40337, 7428, ENSG00000134086, RCA1, VHL1
131 results:
1. Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer.
Li Y; Li G; Zuo C; Wang X; Han F; Jia Y; Shang H; Tian Y
Eur J Med Chem; 2024 Apr; 270():116367. PubMed ID: 38581732
[TBL] [Abstract] [Full Text] [Related]
2. vhl suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation.
Wang Z; Yan M; Ye L; Zhou Q; Duan Y; Jiang H; Wang L; Ouyang Y; Zhang H; Shen Y; Ji G; Chen X; Tian Q; Xiao L; Wu Q; Meng Y; Liu G; Ma L; Lei B; Lu Z; Xu D
EMBO J; 2024 Mar; 43(6):931-955. PubMed ID: 38360997
[TBL] [Abstract] [Full Text] [Related]
3. Fluorescence theranostic PROTACs for real-time visualization of ERα degradation.
Wang X; Xin L; Deng X; Dong C; Hu G; Zhou HB
Eur J Med Chem; 2024 Mar; 267():116184. PubMed ID: 38320426
[TBL] [Abstract] [Full Text] [Related]
4. Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2.
Velez J; Dale B; Park KS; Kaniskan HÜ; Yu X; Jin J
Eur J Med Chem; 2024 Mar; 267():116154. PubMed ID: 38295690
[TBL] [Abstract] [Full Text] [Related]
5. Design, synthesis, and evaluation of vhl-based EZH2 degraders for breast cancer.
Xiao B; Shi Z; Liu J; Huang Q; Shu K; Liu F; Zhi C; Zhang D; Wu L; Yang S; Zeng X; Fan T; Liu Z; Jiang Y
Bioorg Chem; 2024 Feb; 143():107078. PubMed ID: 38181661
[TBL] [Abstract] [Full Text] [Related]
6. NMR-identification of the interaction between Brca1 and the intrinsically disordered monomer of the Myc-associated factor X.
Epasto LM; Pötzl C; Peterlik H; Khalil M; Saint-Pierre C; Gasparutto D; Sicoli G; Kurzbach D
Protein Sci; 2024 Jan; 33(1):e4849. PubMed ID: 38037490
[TBL] [Abstract] [Full Text] [Related]
7. Glutathione-responsive PROTAC for targeted degradation of ERα in breast cancer cells.
Zhou Z; Fan H; Yu D; Shi F; Li Q; Zhang Z; Wang X; Zhang X; Dong C; Sun H; Mi W
Bioorg Med Chem; 2023 Dec; 96():117526. PubMed ID: 38008041
[TBL] [Abstract] [Full Text] [Related]
8. UBE3B promotes breast cancer progression by antagonizing HIF-2α degradation.
Wang Y; Liu X; Wang M; Wang Y; Wang S; Jin L; Liu M; Zhou J; Chen Y
Oncogene; 2023 Nov; 42(46):3394-3406. PubMed ID: 37783786
[TBL] [Abstract] [Full Text] [Related]
9. Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer.
Lee K; Lee J; Choi J; Sim SH; Kim JE; Kim MH; Park YH; Kim JH; Koh SJ; Park KH; Kang MJ; Ahn MS; Lee KE; Kim HJ; Ahn HK; Kim HJ; Park KU; Park IH
Sci Rep; 2023 Jun; 13(1):9928. PubMed ID: 37336919
[TBL] [Abstract] [Full Text] [Related]
10. Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy.
Zakaria NH; Hashad D; Saied MH; Hegazy N; Elkayal A; Tayae E
Hum Genomics; 2023 May; 17(1):43. PubMed ID: 37202799
[TBL] [Abstract] [Full Text] [Related]
11. Integrated Metabolomic and Transcriptomic Analysis of Modified Nucleosides for Biomarker Discovery in Clear Cell Renal Cell Carcinoma.
Mohl DA; Lagies S; Zodel K; Zumkeller M; Peighambari A; Ganner A; Plattner DA; Neumann-Haefelin E; Adlesic M; Frew IJ; Kammerer B
Cells; 2023 Apr; 12(8):. PubMed ID: 37190010
[TBL] [Abstract] [Full Text] [Related]
12. PIN1 and CDK1 cooperatively govern pvhl stability and suppressive functions.
Chen J; Li M; Liu Y; Guan T; Yang X; Wen Y; Zhu Y; Xiao Z; Shen X; Zhang H; Tang H; Liu T
Cell Death Differ; 2023 Apr; 30(4):1082-1095. PubMed ID: 36813923
[TBL] [Abstract] [Full Text] [Related]
13. Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative breast cancer.
Adams CM; Mitra R; Xiao Y; Michener P; Palazzo J; Chao A; Gour J; Cassel J; Salvino JM; Eischen CM
Cancer Discov; 2023 May; 13(5):1210-1229. PubMed ID: 36734633
[TBL] [Abstract] [Full Text] [Related]
14. Frequency of Pathogenic Germline Mutations in Early and Late Onset Familial breast cancer Patients Using Multi-Gene Panel Sequencing: An Egyptian Study.
Nassar A; Zekri AN; Kamel MM; Elberry MH; Lotfy MM; Seadawy MG; Hassan ZK; Soliman HK; Lymona AM; Youssef ASE
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672847
[TBL] [Abstract] [Full Text] [Related]
15. Health education actions on male breast cancer: A protocol for systematic review and meta analysis.
Silva JFCD; Torres GV; Reis LAD; Campos JTAM; Nunes VMA; Santos JCC; Barbalho TNS; Xavier Nobre TT
Medicine (Baltimore); 2022 Oct; 101(42):e30931. PubMed ID: 36281187
[TBL] [Abstract] [Full Text] [Related]
16. Disclosure of genetic risk to dating partners among young adults with von Hippel-Lindau disease.
Bond E; Yashar B; Else T; Osborne J; Marvin M
Fam Cancer; 2023 Apr; 22(2):203-215. PubMed ID: 35984582
[TBL] [Abstract] [Full Text] [Related]
17. Current Systemic Treatments for the Hereditary cancer Syndromes: Drug Development in Light of Genomic Defects.
Hasanov E; Pimentel I; Cruellas M; Lewis MA; Jonasch E; Balmaña J
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-17. PubMed ID: 35671435
[TBL] [Abstract] [Full Text] [Related]
18. Clinical considerations for the design of PROTACs in cancer.
Nieto-Jiménez C; Morafraile EC; Alonso-Moreno C; Ocaña A
Mol Cancer; 2022 Mar; 21(1):67. PubMed ID: 35249548
[TBL] [Abstract] [Full Text] [Related]
19. TET2 Suppresses vhl Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
Zhang X; Li S; He J; Jin Y; Zhang R; Dong W; Lin M; Yang Y; Tian T; Zhou Y; Xu Y; Lei QY; Zhang J; Zhang Q; Xu Y; Lv L
Cancer Res; 2022 Jun; 82(11):2097-2109. PubMed ID: 35176127
[TBL] [Abstract] [Full Text] [Related]
20. TARBP2 Suppresses Ubiquitin-Proteasomal Degradation of HIF-1α in breast cancer.
Li JN; Chen PS; Chiu CF; Lyu YJ; Lo C; Tsai LW; Wang MY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008634
[TBL] [Abstract] [Full Text] [Related]
[Next]
